首页>
外国专利>
Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway
Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway
展开▼
机译：选择非小细胞肺癌患者用靶向EGFR途径的单克隆抗体药物治疗
展开▼
页面导航
摘要
著录项
相似文献
摘要
Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer (NSCLC) patient is likely to benefit from a monoclonal antibody drug targeting an epidermal growth factor receptor pathway. A mass spectrum is obtained from a sample (e.g. blood sample) from the patient. One or more predefined pre-processing steps are performed on the mass spectrum. Values of selected features in the spectrum at one or more predefined m/z ranges are obtained after the pre-processing steps have been performed. Such values are used in a classification algorithm using a training set comprising class-labeled spectra produced from samples from other patients to identify the patient as being likely to benefit from treatment with the drug.
展开▼
